Published in Nat Rev Neurosci on April 01, 2002
Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest (2005) 1.95
Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 1.79
Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. J Clin Invest (2007) 1.67
Astrocytes in multiple sclerosis: a product of their environment. Cell Mol Life Sci (2008) 1.66
Mechanisms of primary axonal damage in a viral model of multiple sclerosis. J Neurosci (2009) 1.65
Environmental factors and their timing in adult-onset multiple sclerosis. Nat Rev Neurol (2010) 1.64
Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci U S A (2004) 1.49
Brain regeneration in physiology and pathology: the immune signature driving therapeutic plasticity of neural stem cells. Physiol Rev (2011) 1.40
Activation of microglial poly(ADP-ribose)-polymerase-1 by cholesterol breakdown products during neuroinflammation: a link between demyelination and neuronal damage. J Exp Med (2003) 1.25
Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J Exp Med (2006) 1.25
Estrogen and testosterone therapies in multiple sclerosis. Prog Brain Res (2009) 1.22
Advances in the understanding of the mechanism of action of IVIg. J Neurol (2008) 1.15
The benefits and detriments of macrophages/microglia in models of multiple sclerosis. Clin Dev Immunol (2013) 1.14
Matrix metalloproteinase proteolysis of the myelin basic protein isoforms is a source of immunogenic peptides in autoimmune multiple sclerosis. PLoS One (2009) 1.11
PPAR Regulation of Inflammatory Signaling in CNS Diseases. PPAR Res (2008) 1.11
Atacicept: targeting B cells in multiple sclerosis. Ther Adv Neurol Disord (2010) 1.08
Inhibition of midkine alleviates experimental autoimmune encephalomyelitis through the expansion of regulatory T cell population. Proc Natl Acad Sci U S A (2008) 1.07
Neurological functional recovery after thymosin beta4 treatment in mice with experimental auto encephalomyelitis. Neuroscience (2009) 1.03
Extensive infiltration of neutrophils in the acute phase of experimental autoimmune encephalomyelitis in C57BL/6 mice. Histochem Cell Biol (2010) 1.02
Animal Models of MS Reveal Multiple Roles of Microglia in Disease Pathogenesis. Neurol Res Int (2011) 1.00
Fas ligand-mediated apoptosis in degenerative disorders of the brain. J Clin Immunol (2003) 0.99
Autoantibody-mediated demyelination depends on complement activation but not activatory Fc-receptors. Proc Natl Acad Sci U S A (2006) 0.98
Viral expression of CCL2 is sufficient to induce demyelination in RAG1-/- mice infected with a neurotropic coronavirus. J Virol (2005) 0.97
Virus-induced demyelination in nude mice is mediated by gamma delta T cells. Am J Pathol (2002) 0.97
Absence of the cellular prion protein exacerbates and prolongs neuroinflammation in experimental autoimmune encephalomyelitis. Am J Pathol (2008) 0.95
Increased expression of cystine/glutamate antiporter in multiple sclerosis. J Neuroinflammation (2011) 0.94
PD-1 Interaction with PD-L1 but not PD-L2 on B-cells Mediates Protective Effects of Estrogen against EAE. J Clin Cell Immunol (2013) 0.94
ICV-transplanted human glial precursor cells are short-lived yet exert immunomodulatory effects in mice with EAE. Glia (2012) 0.93
Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol (2005) 0.93
Microglial cell dysregulation in brain aging and neurodegeneration. Front Aging Neurosci (2015) 0.92
N-acetyl-L-cysteine ameliorates the inflammatory disease process in experimental autoimmune encephalomyelitis in Lewis rats. J Autoimmune Dis (2005) 0.92
Effects of caspase-1 knockout on chronic neural recording quality and longevity: insight into cellular and molecular mechanisms of the reactive tissue response. Biomaterials (2014) 0.92
Virus-specific antibody, in the absence of T cells, mediates demyelination in mice infected with a neurotropic coronavirus. Am J Pathol (2005) 0.90
A mechanism of virus-induced demyelination. Interdiscip Perspect Infect Dis (2010) 0.90
Cell therapy for multiple sclerosis. Neurotherapeutics (2011) 0.89
Heparanase upregulates Th2 cytokines, ameliorating experimental autoimmune encephalitis. Mol Immunol (2010) 0.89
Bystander CD8 T-cell-mediated demyelination is interferon-gamma-dependent in a coronavirus model of multiple sclerosis. Am J Pathol (2004) 0.89
Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats. Proc Natl Acad Sci U S A (2005) 0.88
Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis. J Cent Nerv Syst Dis (2014) 0.87
Chemokines and chemokine receptors in multiple sclerosis. Mediators Inflamm (2014) 0.86
A Diet Mimicking Fasting Promotes Regeneration and Reduces Autoimmunity and Multiple Sclerosis Symptoms. Cell Rep (2016) 0.86
Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway. Int J Mol Sci (2015) 0.86
Important roles for gamma interferon and NKG2D in gammadelta T-cell-induced demyelination in T-cell receptor beta-deficient mice infected with a coronavirus. J Virol (2005) 0.85
Blood-brain barrier permeability of normal appearing white matter in relapsing-remitting multiple sclerosis. PLoS One (2013) 0.85
Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurol Neuroimmunol Neuroinflamm (2015) 0.85
Allopregnanolone and neuroinflammation: a focus on multiple sclerosis. Front Cell Neurosci (2014) 0.84
B-cell delivered gene therapy for tolerance induction: role of autoantigen-specific B cells. J Autoimmun (2010) 0.84
Immunomodulation by transplanted human embryonic stem cell-derived oligodendroglial progenitors in experimental autoimmune encephalomyelitis. Stem Cells (2012) 0.83
New approaches to investigating heterogeneity in complex traits. J Med Genet (2003) 0.83
What do we know about the mechanism of action of disease-modifying treatments in MS? J Neurol (2004) 0.83
Affinity and catalytic heterogeneity of polyclonal myelin basic protein-hydrolyzing IgGs from sera of patients with multiple sclerosis. J Cell Mol Med (2009) 0.83
VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis. Cell Mol Neurobiol (2014) 0.83
RNA plasticity and selectivity applicable to therapeutics and novel biosensor development. Genes Cells (2012) 0.82
The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis. J Neuroinflammation (2013) 0.82
Mitomycin C-treated dendritic cells inactivate autoreactive T cells: toward the development of a tolerogenic vaccine in autoimmune diseases. Proc Natl Acad Sci U S A (2008) 0.81
Niaspan treatment improves neurological functional recovery in experimental autoimmune encephalomyelitis mice. Neurobiol Dis (2008) 0.81
An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. Brain Behav (2015) 0.80
Immunology and neurology. J Neurol (2007) 0.80
Differential expression of CD150 (SLAM) on monocytes and macrophages in chronic inflammatory contexts: abundant in Crohn's disease, but not in multiple sclerosis. J Clin Pathol (2005) 0.80
The effect of vitamin A supplementation on stimulated T-cell proliferation with myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. J Neurosci Rural Pract (2012) 0.80
Defining a new biomarker for the autoimmune component of Multiple Sclerosis: Th40 cells. J Neuroimmunol (2014) 0.80
Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis. J Neurol (2005) 0.79
Identifying genetic loci and spleen gene coexpression networks underlying immunophenotypes in BXD recombinant inbred mice. Physiol Genomics (2010) 0.79
Differential roles of resident microglia and infiltrating monocytes in murine CNS autoimmunity. Semin Immunopathol (2015) 0.79
Carcinoembryonic antigen-related cell adhesion molecule 1 modulates experimental autoimmune encephalomyelitis via an iNKT cell-dependent mechanism. Am J Pathol (2009) 0.79
Midkine and multiple sclerosis. Br J Pharmacol (2014) 0.79
Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis. Immunology (2006) 0.78
Fas ligand-mediated apoptosis in degenerative disorders of the brain. J Clin Immunol (2003) 0.78
Mesenchymal stem cells are mobilized from the bone marrow during inflammation. Front Immunol (2013) 0.77
The Non-Obese Diabetic Mouse Strain as a Model to Study CD8(+) T Cell Function in Relapsing and Progressive Multiple Sclerosis. Front Immunol (2015) 0.77
Systemic injection of neural stem/progenitor cells in mice with chronic EAE. J Vis Exp (2014) 0.77
Role of TGFβ signaling in the pathogenesis of Alzheimer's disease. Front Cell Neurosci (2015) 0.77
Conformational studies of immunodominant myelin basic protein 1-11 analogues using NMR and molecular modeling. J Comput Aided Mol Des (2011) 0.76
Changes in different parameters, lymphocyte proliferation and hematopoietic progenitor colony formation in EAE mice treated with myelin oligodendrocyte glycoprotein. J Cell Mol Med (2015) 0.76
Evaluation of locomotor function and microscopic structure of the spinal cord in a mouse model of experimental autoimmune encephalomyelitis following treatment with syngeneic mesenchymal stem cells. Int J Clin Exp Pathol (2015) 0.76
Theranostic implications of nanotechnology in multiple sclerosis: a future perspective. Autoimmune Dis (2012) 0.76
Survival and Functionality of Human Induced Pluripotent Stem Cell-Derived Oligodendrocytes in a Nonhuman Primate Model for Multiple Sclerosis. Stem Cells Transl Med (2016) 0.76
T cell cytokine signatures: Biomarkers in pediatric multiple sclerosis. J Neuroimmunol (2016) 0.76
Fas-Fas Ligand: Checkpoint of T Cell Functions in Multiple Sclerosis. Front Immunol (2016) 0.75
Update on immunopathogenesis and immunotherapy in multiple sclerosis. Immunotargets Ther (2013) 0.75
Homo-β-amino acid containing MBP(85-99) analogs alleviate experimental autoimmune encephalomyelitis. Sci Rep (2015) 0.75
Fish and egg specific immunoglobin e in multiple sclerosis patients. Int J Prev Med (2013) 0.75
The Diverse Roles of Microglia in the Neurodegenerative Aspects of Central Nervous System (CNS) Autoimmunity. Int J Mol Sci (2017) 0.75
Classification of time series gene expression in clinical studies via integration of biological network. PLoS One (2013) 0.75
The effect of vitamin a supplementation on biochemical parameters in multiple sclerosis patients. Iran Red Crescent Med J (2013) 0.75
Lack of association between rs1800795 (-174 G/C) polymorphism in the promoter region of interleukin-6 gene and susceptibility to type 2 diabetes in Isfahan population. Adv Biomed Res (2016) 0.75
Genetic association of rs1520333 G/A polymorphism in the IL7 gene with multiple sclerosis susceptibility in Isfahan population. Adv Biomed Res (2014) 0.75
CCR5 knockout suppresses experimental autoimmune encephalomyelitis in C57BL/6 mice. Oncotarget (2016) 0.75
Spinal cord injury is related to an increased risk of multiple sclerosis: a population-based, propensity score-matched, longitudinal follow-up study. J Neurotrauma (2015) 0.75
Gliopathy of Demyelinating and Non-Demyelinating Strains of Mouse Hepatitis Virus. Front Cell Neurosci (2015) 0.75
Suppression of immune system genes by methylprednisolone in exacerbations of multiple sclerosis. Preliminary results. J Neurol (2004) 0.75
Stem cell therapy for central nervous system demyelinating disease. Curr Neurol Neurosci Rep (2005) 0.75
Anemoside A3 ameliorates experimental autoimmune encephalomyelitis by modulating T helper 17 cell response. PLoS One (2017) 0.75
The Effect of Osteopontin on Microglia. Biomed Res Int (2017) 0.75
Gut-CNS-Axis as Possibility to Modulate Inflammatory Disease Activity-Implications for Multiple Sclerosis. Int J Mol Sci (2017) 0.75
A meta-analysis to determine the efficacy and tolerability of anti-B-cell monoclonal antibodies in multiple sclerosis. Exp Ther Med (2017) 0.75
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (2010) 13.82
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Guillain-Barré syndrome. N Engl J Med (2012) 6.28
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet (2012) 4.25
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet (2012) 3.89
Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol (2008) 3.59
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol (2009) 3.42
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology (2014) 3.27
Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol (2010) 3.26
Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy. Am J Hum Genet (2003) 3.22
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol (2011) 3.16
Acute disseminated encephalomyelitis: an update. Arch Neurol (2005) 2.45
Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis (2010) 2.32
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol (2011) 2.19
Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol (2012) 2.12
Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med (2007) 2.06
Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology (2005) 2.06
The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood (2008) 2.01
Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain (2005) 1.92
Macrophages prevent hemorrhagic infarct transformation in murine stroke models. Ann Neurol (2012) 1.84
Chronic inflammatory demyelinating polyneuropathy. N Engl J Med (2005) 1.79
Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 1.79
Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler (2012) 1.77
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol (2013) 1.76
More on PML in Patients Treated with Dimethyl Fumarate. N Engl J Med (2016) 1.73
Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol (2004) 1.69
Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies. J Neurol Neurosurg Psychiatry (2012) 1.66
Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Trends Pharmacol Sci (2003) 1.65
Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage. Brain (2007) 1.63
Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler (2011) 1.57
Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis. Neurology (2013) 1.56
Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol (2006) 1.54
Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E epsilon4 allele. Arch Neurol (2003) 1.48
Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation (2012) 1.47
Towards individualised multiple-sclerosis therapy. Lancet Neurol (2005) 1.46
Neuromyelitis optica following human papillomavirus vaccination. Neurology (2012) 1.44
Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis. Arch Neurol (2009) 1.42
Evidence for use of glatiramer acetate in multiple sclerosis. Lancet Neurol (2005) 1.40
Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis. Expert Opin Pharmacother (2012) 1.40
Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol (2003) 1.39
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol (2010) 1.37
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol (2007) 1.36
Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol (2010) 1.36
Acute disseminated encephalomyelitis: an acute hit against the brain. Curr Opin Neurol (2007) 1.34
Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. Mult Scler (2013) 1.30
Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. J Neuroimmunol (2009) 1.28
Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol (2013) 1.27
Phenotypes of the N88S Berardinelli-Seip congenital lipodystrophy 2 mutation. Ann Neurol (2005) 1.25
Enhancing remyelination in disease--can we wrap it up? Brain (2011) 1.25
Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs (2008) 1.25
Optical coherence tomography in parkinsonian syndromes. PLoS One (2012) 1.24
In vivo MRI of brain inflammation in human ischaemic stroke. Brain (2004) 1.24
Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography. Mult Scler Int (2012) 1.24
Cerebrospinal fluid of brain trauma patients inhibits in vitro neuronal network function via NMDA receptors. Ann Neurol (2009) 1.24
Animal models of multiple sclerosis--potentials and limitations. Prog Neurobiol (2010) 1.23
Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis (2009) 1.22
Autosomal dominant inherited neuropathies with prominent sensory loss and mutilations: a review. Arch Neurol (2003) 1.22
The complex world of oligodendroglial differentiation inhibitors. Ann Neurol (2011) 1.19
Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders. Arch Neurol (2006) 1.17
New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol (2009) 1.15
From bench to bedside--experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol (2007) 1.14
Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol (2005) 1.13
Remyelinating strategies for the treatment of multiple sclerosis. Prog Neurobiol (2002) 1.12
Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat (2009) 1.12
Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol (2010) 1.11
Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol (2005) 1.10
Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol (2007) 1.09
Increased thalamic neurodegeneration following ischaemic cortical stroke in osteopontin-deficient mice. Brain (2006) 1.09
Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler (2012) 1.09
Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve (2004) 1.09
Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain (2002) 1.08
Viral load determines the B-cell response in the cerebrospinal fluid during human immunodeficiency virus infection. Ann Neurol (2007) 1.08
Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci (2010) 1.07
Peripheral neuropathy: assessment of proximal nerve integrity by diffusion tensor imaging. Muscle Nerve (2013) 1.06
Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy. Clin Immunol (2011) 1.06
Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler (2012) 1.04
Human endogenous retrovirus type W envelope protein inhibits oligodendroglial precursor cell differentiation. Ann Neurol (2013) 1.04
Iron oxide particle-enhanced MRI suggests variability of brain inflammation at early stages after ischemic stroke. Stroke (2007) 1.03
Immune circuitry in the peripheral nervous system. Curr Opin Neurol (2006) 1.03
Revised McDonald criteria: the persisting importance of cerebrospinal fluid analysis. Ann Neurol (2011) 1.02
Development and pharmacological modulation of embryonic stem cell-derived neuronal network activity. Exp Neurol (2007) 1.02
Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. Arch Neurol (2007) 1.01
Current disease-modifying therapies in multiple sclerosis. Semin Neurol (2003) 1.01
Statins--a cure-all for the brain? Nat Rev Neurosci (2005) 1.00
Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol (2014) 0.99
Activation of CXCR7 receptor promotes oligodendroglial cell maturation. Ann Neurol (2010) 0.99
Niche-dependent development of functional neuronal networks from embryonic stem cell-derived neural populations. BMC Neurosci (2009) 0.98
CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. Mult Scler (2010) 0.98
HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet (2008) 0.98
Osteopontin, a macrophage-derived matricellular glycoprotein, inhibits axon outgrowth. FASEB J (2004) 0.97
Active immunization induces toxicity of diphtheria toxin in diphtheria resistant mice--implications for neuroinflammatory models. J Immunol Methods (2010) 0.96
Impact of HMG-CoA reductase inhibition on brain pathology. Trends Pharmacol Sci (2007) 0.96
European validation of a standardized clinical description of multiple sclerosis. J Neurol (2004) 0.96
Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. J Neurol (2007) 0.96
Neurofilament ELISA validation. J Immunol Methods (2009) 0.96